Form4insider filings, from the source

SEC Form 4 · accession 0001209191-17-002190

Vanda Pharmaceuticals Inc. · VNDA

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner
Mihael Hristos Polymeropoulos
Officer — President and CEO · Director
Period of report
Jan 3, 2017
Accepted (ET)
Jan 5, 2017 · 4:58 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001347178

Table I — non-derivative securities

SecurityDateCodeSharesPriceA/DOwned afterD/INature of ownership
Common StockF1Jan 3, 2017M6,250—A830,428D
Common StockF1Jan 3, 2017M12,500—A842,928D
Common StockF1Jan 3, 2017M12,500—A855,428D
Common StockF1Jan 3, 2017M18,750—A874,178D
Common StockF3Jan 3, 2017S23,330$15.484D850,848D

Table II — derivative securities

SecurityConv. / exercise priceDateCodeSharesA/DExercisableExpiresUnderlyingUnderlying sharesOwned afterD/I
Restricted Stock UnitF1,F4,F5—Jan 3, 2017M6,250D——Common Stock6,2500D
Restricted Stock UnitF1,F6,F5—Jan 3, 2017M12,500D——Common Stock12,50012,500D
Restricted Stock UnitF1,F7,F5—Jan 3, 2017M12,500D——Common Stock12,50025,000D
Restricted Stock UnitF1,F8,F5—Jan 3, 2017M18,750D——Common Stock18,75056,250D

Explanation of responses